Funding

PART B: VALORISATION PLAN

SECTION I: ESTIMATION OF COSTS

 

1

Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
… in terms of IPR protection
No IPR protection is foreseen. There are already some examples of similar patents (MIT, Apple…). A patent for CAB will not be impregnable.

 

…in terms of product development
Staff costs are needed: at least 2 people (experts, engineers) for 1 year fully employed.

 

…in terms of mass production
No costs foreseen.

 

… in terms of marketing
A big investment has to be planned in order to reach the attention of venture capitalists, directly or through intermediary actions: 50 -100.000€

 

 

2

Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs

Year 1

Year 2

Year 3

Year 4

Year 5

Fixed costs

6.000

4.000

4.000

Personnel

90.000

45.000

45.000

Other running costs

-

-

-

Marketing costs

50.000

80.000

60.000

TOTAL EXPECTED COSTS

146.000

129.000

109.000

Price per Unit

-

-

-

Type of Unit

Number of Units

-

-

-

TOTAL Expected Revenues

175.000

CASH FLOW REQUIRED (REVENUES-COSTS)

-146.000

-129.000

+66.000

TOTAL CAPITAL required for five years

There is a need of at least 280.000 € during the first year and a half in order to produce the right product and reach the identified Lead User.

 

 

SECTION 2: QUALITATIVE FACTORS

 

3

Dimension of identified target groups
Identified target groups are big Lead Users in the field of phone and media communication that can improve the product in different field of activities.

Another important target has to be taken into account: the so called end users, big players, public or private, that can be targeted as vehicle to reach the Lead Users. For examples, a City can provide its tourists with a touristic guide accessible via mobile phone; this means that in different parts of the town centre, phone applications have to be installed and the tourist, while walking, will have all the right information at the right place in the right time! In this way, the City can be considered an important target as will represent the demand for the Lead Users.

 

4

Evaluation of financial Risks for R&D result
Although CAB is a very general software able to adapt to every domain, several features have always to be taken into account (it’s a sum of parts) and its generality could represent a weakness when approaching the market. In order to avoid financial risks, an investment in the CAB application should be done only addressing a specific domain.

 

 

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

 

1. European Funding

Define relevance of the product with the following potential funding sources and comment

  1. 1.  FP7 Programme – ICT work programme to be explored with attention to Cooperation calls

http://cordis.europa.eu/fp7/ict/home_en.html

  1. 2.  CIP-ICT-PSP – Work programme 2011

http://ec.europa.eu/information_society/activities/ict_psp/index_en.htm

For further develop the Research, in cooperation with EU partners, the two above mentioned EU programmes can be addressed.

  1. 3.  Interreg programme

The group is already participating in Interreg cross-border projects (i.e. Interreg Italia-Austria). Also Interreg Italia-Slovenia and other initiatives of crossborder or interregional cooperation could be addressed, but these kind of opportunities are more networking oriented then research oriented. This programme could be useful for the development of EU contacts and useful links, but it does not represent the best choice for R&D.

 

 

2. National Funding

n.a.

 

3. Private funding

1. Venture capitalist

The CAB application needs to be implemented into the market with a start up investment. A venture capital would be the best solution at this stage.

 

 

4. Other

           Regional funding for Applied Research in cooperation with local companies (LR 26, LR4, POR-FESR). In these cases, the applicant is generally the company (that have the specific interest to develop a Research and is willing to invest on that – the regional funds is only covering a part of the costs, there is always a partner co financing).

 

 

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
 The R&D has a high potential of exploitation. A spin off has already been created and it demonstrated the market possibilities.

Further research work is still in progress and till now it has represented the main activity. Now it’s time for the group to change priority: a managerial approach is needed in order to reach the right market.

Marketing is needed and it represents the higher cost to face.

 

 

 

Decision of evaluation (Please keep only the appropriate)

  • The R&D has a high potential of exploitation
  • The R&D result needs minor revisions
  • The R&D result needs moderate revisions
  • The R&D result needs major revisions
  • The R&D result has no potential of exploitation

 

 

 

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project